Marchi LF, et al. - The functional activity of peripheral blood neutrophils and the complement system activation status was evaluated in subjects with rheumatoid arthritis (RA) who underwent infliximab/methotrexate combined therapy. Although disease remission was noted to be induced by infliximab/methotrexate combined therapy according to the DAS-28 (Disease activity score of 28 joints) criteria, significant levels of systemic activation of neutrophils and the complement system were still exhibited by both inactive rheumatoid arthritis (i-RA) and active rheumatoid arthritis (a-RA) patients.